全球化學塗層氣球市場：市場規模、佔有率和趨勢分析（2025-2032 年）

全球化學塗層氣球市場報告

2025年全球藥用塗層球囊市場規模為5.23億美元。預計該市場在預測期內將以5%的複合年成長率成長，到2032年達到約7.35億美元。

• 這份關於全球化學塗層氣球市場的綜合報告涵蓋七個地區：北美、拉丁美洲、西歐、中東歐、中東、亞太地區和非洲。報告針對每個區域，提供詳細的市場規模、銷售量分析、平均售價數據、至2032年的預測以及截至2022年的歷史數據。報告結構遵循附件範例文件中概述的最佳實踐格式，確保市場細分、競爭基準分析和調查方法的一致性。

本報告重點分析了全球藥用塗層球囊市場，包括銷售量、手術量、平均售價、市場規模、成長趨勢、市場佔有率和預測。該報告還涵蓋了市場促進因素和限制因素的定性分析、近期併購、公司概況、產品系列以及主要參與者之間的競爭地位。

推動該市場發展的關鍵趨勢是塗層技術的不斷改進和臨床應用的拓展。製造商正在提高藥物輸送效率、塗層耐久性和生物相容性，改善臨床療效。同時，藥物塗層球囊的應用範圍也從傳統的周邊血管介入擴展到微血管、分叉病變和支架內再血管再阻塞等領域。這些因素推動了市場穩定成長，並鞏固了藥物塗層球囊作為多功能介入治療工具的地位。

儘管前景樂觀，但市場仍受到紫杉醇類技術相關擔憂的影響。這些擔憂正在影響醫生的行為，並減緩某些地區技術的普及速度。因此，雖然藥物塗層球囊市場的成長速度超過許多其他球囊類別，但其擴張仍依賴臨床信心、持續的研發以及下一代藥物平台的開發。

市場概覽

全球藥物塗層球囊市場包括塗覆抗增生藥物的導管式血管成形術用氣球，旨在減少血管擴張後的血管再阻塞。與僅依賴機械擴張的傳統球囊血管成形術不同，藥物塗層球囊在充氣過程中將藥物直接輸送到血管壁，有助於預防治療部位的血管再阻塞。

這些裝置主要用於周邊血管介入治療，包括表動脈手術和動靜脈通路介入治療。它們在微血管疾病和支架內再血管再阻塞等更專業的適應症中也越來越受歡迎。由於它們無需植入永久性植入即可治療病變，因此在長期血管柔軟性和未來治療選擇至關重要的情況下，它們成為極具吸引力的選擇。

藥物塗層球囊市場介於標準經皮腔內血管成形術（PTA）球囊和支架治療方法之間。與標準球囊相比，藥物塗層球囊在某些情況下可提供更佳的長期治療效果。與支架相比，它們提供了一種無需植入的替代方案，從而降低了與永久性裝置相關的併發症風險。這種市場定位賦予了它們在現代血管內治療策略中獨特的地位。

整體而言，藥物釋放型球囊市場的特點是穩定成長、持續創新，以及臨床證據與商業性成功之間的強相關性。

市場促進因素

藥物塗層球囊的臨床結果

藥物塗層球囊市場的主要驅動力之一是眾多研究中展現出的卓越臨床效果。臨床試驗表明，與標準球囊相比，藥物塗層球囊能夠改善長期治療效果，尤其是在降低血管再阻塞。這使其成為那些關注球囊耐久性的病變治療醫生的理想選擇。

由於這些裝置不會留下永久性植入，因此它們也適用於旨在保護血管解剖結構並保持柔軟性以利於未來治療的治療策略。這在周邊血管疾病中尤其重要，因為這類患者可能需要隨著時間的推移接受多次介入治療。

擴大複雜病變部位的採用率

另一個重要的促進因素是藥物釋放型球囊的應用範圍不斷擴大，涵蓋了更複雜的病變類型。這些裝置擴大用於治療微血管病變、分叉病變和支架內血管再阻塞。隨著醫師在這些適應症方面累積更多經驗和信心，潛在市場規模也將持續擴大。

膝下外科手術也是一個重要的成長領域。這類手術通常針對較小的血管，而藥物釋放型球囊無需植入支架即可提供有效的治療方案。隨著此類手術數量的增加，對藥物釋放型球囊的需求也預計將相應成長。

價格趨勢和相對價值

雖然藥物塗層球囊比標準PTA球囊更貴，但考慮到手術總成本，其價格通常低於支架植入式治療方法。隨著價格競爭加劇和健保報銷體系的不斷完善，藥物塗層球囊在許多醫療系統中逐漸成為更容易獲得的治療選擇。

隨著平均售價的逐漸降低，預計該產品的普及率將持續提高，尤其是先前因成本問題而限制其推廣的地區。這將為該產品的更廣泛應用鋪平道路，並促進其長期市場成長。

塗層技術的進步

塗層技術的進步也在推動市場擴張。製造商正致力於提高藥物釋放效率、塗層穩定性以及器械的整體性能。這些改進有望帶來更好的臨床療效，並增強醫生的信心。

此外，對替代藥物製劑和給藥方法的研究有助於解決現有藥物平台的相關問題。預計該領域的持續創新將在塑造市場未來方面發揮關鍵作用。

市場限制

對使用紫杉醇的擔憂

藥物塗層球囊市場面臨的最大阻礙因素之一是對紫杉醇使用的擔憂。 2019年初，一項研究顯示紫杉醇塗層器械可能與長期死亡率升高有關，這給市場帶來了巨大衝擊。導致醫師信心急劇下降，器械使用量也隨之減少。

後續研究帶來了新的見解，市場也開始顯現復甦跡象，但這些擔憂的影響仍然存在。醫生們仍然保持謹慎，產品採用率尚未完全恢復到2019年之前的水準。這種情況持續影響著銷售量成長和整體市場價值。

對臨床證據的依賴

藥物塗層球囊市場高度依賴臨床數據。強而有力的證據能夠推動產品快速普及，但負面或不確定的結果也會產生同樣強烈的負面影響。這導致該市場波動性遠超過其他成熟且商品化的醫療設備領域。

為了維持信任並推動產品普及，製造商必須持續投資於臨床試驗、上市後監測和醫生教育。這些要求增加了產品開發和商業化的成本和複雜性。

特定領域的復甦延遲

在藥物塗層球囊市場的某些細分領域，由於紫杉醇帶來的衝擊，復甦步伐放緩。在替代治療方法易於取得或醫生偏好轉向其他技術的地區，這種情況尤其明顯。

因此，這些細分市場的成長預計將是漸進式的，而非快速的。整體市場將持續擴張，但其成長速度不僅反映了市場接受度的恢復，也反映了消費者持續的謹慎態度。

來自替代療法的競爭壓力

藥物塗層球囊也面臨其他治療方法的競爭，例如標準PTA球囊、支架和動脈粥狀硬化斑塊切除術裝置。在某些情況下，醫生可能會根據病變特徵、成本考慮或臨床偏好選擇這些替代方案。

在這種競爭激烈的環境中，藥物塗層球囊必須繼續證明其具有明顯的臨床價值，才能在更廣泛的周邊血管器械市場中維持和擴大其市場佔有率。

市場覆蓋範圍和數據範圍

定量範圍

市場規模、市佔率、市場預測、市場成長率、銷售量、平均售價。

定性研究範圍

市場促進因素與限制因素、競爭分析、公司概況、產品系列、併購以及技術趨勢。

目標期

基準年：2025 年，歷史資料截至 2022 年，預測至 2032 年。

區域分析

北美洲、拉丁美洲、西歐、中歐和東歐、中東、亞太地區、非洲。

包含的資料類型

銷售量、平均售價、治療次數、市場規模和成長趨勢。

本報告對藥用塗層球囊市場進行了詳細而系統性的分析，有助於策略規劃、競爭基準分析和產品定位。

目標市場及區隔

• 本報告涵蓋全球藥物塗層球囊市場，依適應症細分如下：

應用於表動脈

本部分介紹了藥物塗層球囊在治療周邊動脈疾病的案例研究。

應用於動靜脈分流術

本部分內容包括使用藥物塗層球囊來維持和恢復透析通路迴路的通暢性。

競爭分析

2025年，美敦力憑藉其藥物塗層球囊IN.PACT Admiral的成功，在全球藥物塗層球囊市場佔據主導地位。卓越的臨床結果和多家監管機構的核准鞏固了該公司的市場地位，同時，該公司也拓展了其在動脈和靜脈通路應用領域的業務。儘管美敦力目前仍保持著市場領導地位，但隨著競爭加劇，其市場佔有率預計將面臨壓力。

貝克頓·迪金森公司憑藉其「Lutonix」平台，成為藥物塗層球囊市場的早期領導者，該平台是首個獲得美國FDA核准的同類產品。儘管該公司擁有強大的基本客群，但由於新產品的競爭和臨床偏好的變化，預計其市場佔有率未來將會下降。

波士頓科學公司預計到2025年將成為全球第三大公司。其藥物塗層球囊Ranger已獲得FDA核准用於治療周邊動脈疾病，為公司在該領域的擴張提供了有力支撐。透過持續投資血管介入技術，波士頓科學公司已成為市場上的主要競爭者。

總體而言，競爭格局由臨床證據、監管核准以及在各種血管疾病適應症中證明持續療效的能力所決定。

科技和醫療治療的發展趨勢

塗層技術的進步是藥物塗層球囊市場最重要的發展趨勢之一。製造商正致力於提高藥物釋放效率和塗層耐久性，以增強治療效果。

另一個重要趨勢是藥物塗層球囊的適應症不斷擴大。這些裝置擴大用於較小的血管、更複雜的病變類型以及支架內血管再阻塞病例中，從而擴大了其臨床效用。

醫生的治療模式也正朝著盡可能避免永久性植入的治療策略轉變。這促使藥物塗層球囊在適當的病例中作為一種血管保護性治療方案得到應用。

同時，對藥物安全性和長期治療效果的持續評估不斷影響這些藥物的應用方式。這確保了技術發展與臨床證據緊密結合。

地區

本報告提供了涵蓋北美、歐洲、亞太地區、拉丁美洲以及中東和非洲的全球研究成果。

一份長達 55 頁的詳細市場分析、市場區隔和預測報告。

調查方法附錄和簡稱詞彙表。

這份報告的意義

全球化學塗層氣球市場最大的成長機會在哪裡？

塗層技術和臨床應用的擴展將如何影響未來的需求？

安全問題和臨床證據要求如何影響這項技術的應用？

哪些競爭對手在市場中處於領先地位？他們的產品系列是如何演變的？

到 2032 年，價格趨勢和贖回方案將如何影響市場擴張？

醫生們是如何將藥物塗層球囊納入更廣泛的治療策略中的？

iData Research 的《全球藥物塗層球囊市場報告》透過詳細的市場區隔、競爭分析和預測模型解答了這些問題。利用這份報告，您可以評估市場機會、比較競爭對手，並為血管器械這一蓬勃發展的領域中的策略決策提供支援。

目錄

圖表清單

調查方法

• 第一步：計劃啟動與團隊組建
• 步驟 2：準備資料系統並進行二次調查。
• 步驟 3：設計和準備訪談和調查問卷。
• 第四步：進行初步調查
• 第五步：調查與分析：建立基準估計值
• 第六步：市場預測與分析
• 步驟 7：辨識策略機遇
• 步驟 8：最終審核和市場推廣
• 步驟九：客戶回饋與市場監測

全球關稅的影響

藥物塗層氣球市場

• 執行摘要
  • 全球化學塗層球囊市場概覽
  • 競爭分析
  • 目標程式
  • 目標場地
  • 目標區域
• 介紹
• 手術次數
• 市場分析與預測
• 單元分析
  • 按顯示數量銷售
• 促進因素和抑制因素
• 競爭性市佔率分析

簡稱

Global Drug-Coated Balloon Market Report

The global drug-coated balloon market was valued at $523 million in 2025. This market is expected to grow at a CAGR of 5% over the forecast period to reach approximately $735 million by 2032.

• The full report suite on the global market for drug-coated balloons covers seven geographical regions: North America, Latin America, Western Europe, Central and Eastern Europe, the Middle East, Asia-Pacific and Africa. For each region, the report provides detailed market valuation, unit analysis and average selling price data, along with forecasts through 2032 and historical data to 2022. The structure of this report follows the same best-practice format shown in the attached example document, ensuring consistent segmentation, competitive benchmarking and forecasting methodology .

This report provides a focused analysis of the global drug-coated balloon market, including unit sales, procedure numbers, average selling prices, market size, growth trends, market shares and forecasts. It also includes qualitative analysis of market drivers and limiters, recent mergers and acquisitions, company profiles, product portfolios and competitive positioning across key players.

A key trend shaping this market is the continued refinement of coating technologies and the expansion of clinical applications. Manufacturers are improving drug delivery efficiency, coating durability and biocompatibility, which supports better clinical outcomes. At the same time, the use of drug-coated balloons is expanding beyond traditional peripheral applications into areas such as small vessels, bifurcation lesions and in-stent restenosis. These factors are supporting steady growth and reinforcing the role of drug-coated balloons as a versatile tool across multiple interventional settings.

Despite this positive outlook, the market continues to be influenced by lingering concerns around paclitaxel-based technologies. These concerns have shaped physician behavior and slowed adoption in certain regions. As a result, while the drug-coated balloon market is growing faster than many other balloon categories, its expansion remains tied to clinical confidence, continued research and the development of next-generation drug platforms.

Market Overview

The global drug-coated balloon market includes catheter-based angioplasty balloons that are coated with antiproliferative drugs designed to reduce restenosis following vessel dilation. Unlike traditional balloon angioplasty, which relies only on mechanical expansion, drug-coated balloons deliver medication directly to the vessel wall during inflation, helping prevent re-narrowing of the treated segment.

These devices are used primarily in peripheral vascular interventions, including superficial femoral artery procedures and arteriovenous access interventions. They are also gaining traction in more specialized applications, such as small vessel disease and in-stent restenosis. Their ability to treat lesions without leaving a permanent implant has made them an attractive option in cases where long-term vessel flexibility and future treatment options are important.

The drug-coated balloon market sits between standard PTA balloons and stent-based therapies. Compared with standard balloons, drug-coated balloons offer improved long-term outcomes in selected cases. Compared with stents, they provide a non-implant alternative that can reduce the risk of complications associated with permanent devices. This positioning gives them a distinct role in modern endovascular treatment strategies.

Overall, the drug-coated balloon market is characterized by steady growth, ongoing innovation and a strong link between clinical evidence and commercial performance.

Market Drivers

Drug-Coated Balloon Clinical Performance

One of the main drivers of the drug-coated balloon market is the strong clinical performance demonstrated in many studies. Clinical trials have shown that drug-coated balloons can improve long-term outcomes compared with standard balloons, particularly in reducing restenosis. This makes them an attractive option for physicians treating lesions where durability is a concern.

Because these devices do not leave a permanent implant, they also align with treatment strategies that aim to preserve vessel anatomy and maintain future treatment flexibility. This is especially important in peripheral vascular disease, where patients may require multiple interventions over time.

Increasing Adoption in Complex Lesions

The expansion of drug-coated balloon use into more complex lesion types is another key driver. These devices are being used more frequently in small vessels, bifurcation lesions and in-stent restenosis cases. As physicians gain more experience and confidence in these applications, the total addressable market continues to expand.

Below-the-knee procedures are also an important area of growth. These interventions often involve smaller vessels, where drug-coated balloons can provide an effective treatment option without the need for stent placement. As the number of these procedures increases, demand for drug-coated balloons is expected to grow alongside them.

Pricing Dynamics and Relative Value

While drug-coated balloons are more expensive than standard PTA balloons, their price point is often lower than that of stent-based therapies when considering total procedural cost. As pricing becomes more competitive and as reimbursement structures evolve, drug-coated balloons are becoming a more accessible option in many healthcare systems.

As average selling prices decline over time, adoption is expected to increase, particularly in regions where cost sensitivity has previously limited uptake. This creates a pathway for broader use and supports long-term market growth.

Expansion of Coating Technologies

Advancements in coating technology are also driving market expansion. Manufacturers are working to improve drug transfer efficiency, coating stability and overall device performance. These improvements can lead to better clinical outcomes and increased physician confidence.

In addition, research into alternative drug formulations and delivery methods may help address concerns associated with existing drug platforms. Continued innovation in this area is expected to play a key role in shaping the future of the market.

Market Limiters

Concerns Over Paclitaxel Use

One of the most significant limiters in the drug-coated balloon market is the concern over paclitaxel use. In early 2019, the market experienced a major disruption following studies that suggested a potential link between paclitaxel-coated devices and increased long-term mortality. This led to a sharp decline in physician confidence and a reduction in device usage.

Although further research has provided additional context and the market has begun to recover, the impact of these concerns is still present. Physicians remain cautious, and adoption rates have not fully returned to pre-2019 expectations. This continues to influence both unit growth and overall market value.

Dependence on Clinical Evidence

The drug-coated balloon market is highly dependent on clinical data. While strong evidence can support rapid adoption, negative or uncertain findings can have an equally strong impact in the opposite direction. This creates a level of volatility that is not present in more mature and commoditized device categories.

Manufacturers must continue to invest in clinical studies, post-market surveillance and physician education to maintain confidence and support adoption. These requirements add cost and complexity to product development and commercialization.

Slower Recovery in Certain Segments

Some segments of the drug-coated balloon market have been slower to recover following the paclitaxel-related disruption. This is particularly true in areas where alternative treatment options are readily available or where physician preference has shifted toward other technologies.

As a result, growth in these segments is expected to be gradual rather than rapid. The overall market will continue to expand, but at a pace that reflects both renewed adoption and ongoing caution.

Competitive Pressure from Alternative Therapies

Drug-coated balloons also face competition from other treatment modalities, including standard PTA balloons, stents and atherectomy devices. In some cases, physicians may choose these alternatives based on lesion characteristics, cost considerations or clinical preference.

This competitive environment means that drug-coated balloons must continue to demonstrate clear clinical value in order to maintain and grow their share within the broader peripheral vascular device market.

Market Coverage and Data Scope

Quantitative Coverage

Market size, market shares, market forecasts, market growth rates, units sold and average selling prices.

Qualitative Coverage

Market drivers and limiters, competitive analysis, company profiles, product portfolios, mergers and acquisitions and technology trends.

Time Frame

Base year 2025, historical data to 2022 and forecasts through 2032.

Regional Coverage

North America, Latin America, Western Europe, Central and Eastern Europe, the Middle East, Asia-Pacific and Africa.

Data Types Included

Unit sales, average selling prices, procedure numbers, market size and growth trends.

This report provides a detailed and structured view of the drug-coated balloon market, supporting strategic planning, competitive benchmarking and product positioning.

Markets Covered and Segmentation

• The report covers the Global Drug-Coated Balloon Market, segmented by indication into:

Superficial Femoral Artery Applications

This segment represents a core use case for drug-coated balloons in peripheral arterial disease treatment.

Arteriovenous Access Applications

This segment includes the use of drug-coated balloons in maintaining and restoring patency in dialysis access circuits.

Competitive Analysis

Medtronic dominated the global drug-coated balloon market in 2025, driven largely by the success of its IN.PACT Admiral drug-coated balloon. Strong clinical outcomes and multiple regulatory approvals supported its position, including expansion into arteriovenous access applications. While Medtronic remains the market leader, its share is expected to face pressure as competition increases.

Becton Dickinson was an early leader in the drug-coated balloon market with the Lutonix platform, which was the first FDA-approved device of its kind in the United States. Although the company maintained strong account presence, competition from newer devices and evolving clinical preferences is expected to reduce its relative share over time.

Boston Scientific held the third position in 2025. Its Ranger drug-coated balloon gained FDA approval for peripheral arterial disease treatment and has supported the company's expansion in this segment. Boston Scientific's continued investment in vascular intervention technologies positions it as a key competitor in the market.

Overall, the competitive landscape is shaped by clinical evidence, regulatory approvals and the ability to demonstrate consistent performance across different vascular indications.

Technology and Practice Trends

Advancements in coating technology are one of the most important trends in the drug-coated balloon market. Manufacturers are focusing on improving drug transfer efficiency and coating durability in order to enhance treatment outcomes.

The expansion of drug-coated balloon applications is another key trend. These devices are increasingly being used in smaller vessels, more complex lesion types and in-stent restenosis cases, broadening their clinical relevance.

Physician practice patterns are also evolving toward treatment strategies that avoid permanent implants when possible. This supports the use of drug-coated balloons as a vessel-preserving option in appropriate cases.

At the same time, ongoing evaluation of drug safety and long-term outcomes continues to shape adoption patterns. This ensures that technology development remains closely aligned with clinical evidence.

Geography

This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.

55 pages of detailed market analysis, segmentation and forecasts.

Methodology Appendix and Acronym Glossary.

Why This Report

Where are the strongest growth opportunities within the global drug-coated balloon market?

How are coating technologies and expanding clinical applications shaping future demand?

What impact are safety concerns and clinical evidence requirements having on adoption?

Which competitors lead the market and how are their product portfolios evolving?

How will pricing trends and reimbursement influence market expansion through 2032?

How are physicians integrating drug-coated balloons into broader treatment strategies?

The Global Drug-Coated Balloon Market Report from iData Research answers these questions with detailed segmentation, competitive analysis and forecast modeling. Use it to evaluate market opportunities, benchmark competitors and support strategic decision making in a growing vascular device category.

TABLE OF CONTENT

List Of Figures

List Of Charts

Research Methodology

• Step 1: Project Initiation & Team Selection
• Step 2: Prepare Data Systems And Perform Secondary Research
• Step 3: Preparation For Interviews & Questionnaire Design
• Step 4: Performing Primary Research
• Step 5: Research Analysis: Establishing Baseline Estimates
• Step 6: Market Forecast And Analysis
• Step 7: Identify Strategic Opportunities
• Step 8: Final Review And Market Release
• Step 9: Customer Feedback And Market Monitoring

Impact Of Global Tariffs

Drug-Coated Balloon Market

• 6.1 Executive Summary
  • 6.1.1 Global Drug-Coated Balloon Market Overview
  • 6.1.2 Competitive Analysis
  • 6.1.3 Procedures Included
  • 6.1.4 Market Included
  • 6.1.5 Regions Included
• 6.2 Introduction
• 6.3 Procedure Numbers
• 6.4 Market Analysis And Forecast
• 6.5 Unit Analysis
  • 6.5.1 Unit Sold By Indication
• 6.6 Drivers And Limiters
  • 6.6.1 Market Drivers
  • 6.6.2 Market Limiters
• 6.7 Competitive Market Share Analysis

Abbreviations

LIST OF CHARTS

• Chart 6-1: Drug-Coated Balloon Market, Global, 2025 & 2032
• Chart 6-2: Drug-Coated Balloon Procedures, Global, 2025
• Chart 6-3: Drug-Coated Balloon Procedures by Region, Global, 2022 - 2032
• Chart 6-4: Drug-Coated Balloon Market, Global, 2022 - 2032
• Chart 6-5: Leading Competitors, Drug-Coated Balloon Market, Global, 2025

LIST OF FIGURES

• Figure 6-1: Drug-Coated Balloon Procedures Covered
• Figure 6-2: Drug-Coated Balloon Regions Covered, Global (1 of 2)
• Figure 6-3: Drug-Coated Balloon Regions Covered, Global (2 of 2)
• Figure 6-4: Drug-Coated Balloon Procedures by Region, Global, 2022 - 2032
• Figure 6-5: Drug-Coated Balloon Procedures by Country, North America, 2022 - 2032
• Figure 6-6: Drug-Coated Balloon Procedures by Country, Latin America, 2022 - 2032 (1 of 2)
• Figure 6-7: Drug-Coated Balloon Procedures by Country, Latin America, 2022 - 2032 (2 of 2)
• Figure 6-8: Drug-Coated Balloon Procedures by Country, Western Europe, 2022 - 2032
• Figure 6-9: Drug-Coated Balloon Procedures by Country, Central & Eastern Europe, 2022 - 2032 (1 of 2)
• Figure 6-10: Drug-Coated Balloon Procedures by Country, Central & Eastern Europe, 2022 - 2032 (2 of 2)
• Figure 6-11: Drug-Coated Balloon Procedures by Country, Middle East, 2022 - 2032
• Figure 6-12: Drug-Coated Balloon Procedures by Country, Asia-Pacific, 2022 - 2032 (1 of 3)
• Figure 6-13: Drug-Coated Balloon Procedures by Country, Asia-Pacific, 2022 - 2032 (2 of 3)
• Figure 6-14: Drug-Coated Balloon Procedures by Country, Asia-Pacific, 2022 - 2032 (3 of 3)
• Figure 6-15: Drug-Coated Balloon Procedures by Country, Africa, 2022 - 2032
• Figure 6-16: Drug-Coated Balloon Market, Global, 2022 - 2032
• Figure 6-17: Units Sold by Region, Drug-Coated Balloon Market, Global, 2022 - 2032
• Figure 6-18: Average Selling Price by Region, Drug-Coated Balloon Market, Global, 2022 - 2032 (US$)
• Figure 6-19: Market Value by Region, Drug-Coated Balloon Market, Global, 2022 - 2032 (US$M)
• Figure 6-20: Drug-Coated Balloon Unit Analysis by Indication, Global, 2022 - 2032
• Figure 6-21: Units Sold by Region, SFA Drug-Coated Balloon Market, Global, 2022 - 2032
• Figure 6-22: Units Sold by Region, AV Access Drug-Coated Balloon Market, Global, 2022 - 2032
• Figure 6-23: Leading Competitors, Drug-Coated Balloon Market, Global, 2025